LYELL IMMUNOPHARMA INC (LYEL) Stock Analyst Earnings Estimates
NASDAQ:LYEL - Nasdaq - US55083R1041 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 84.68M 695.12% | 130K -99.85% | 61K -53.08% | 8.67K -85.79% | -100.00% | 31.11K | |
| EBITDA YoY % growth | -169.04M 15.84% | -226.758M -34.14% | -200.643M 11.52% | -204.9M -2.12% | -212.828M -3.87% | -258.349M -21.39% | |
| EBIT YoY % growth | -187.06M 12.78% | -247.008M -32.05% | -220.274M 10.82% | -219.106M 0.53% | -217.61M 0.68% | -235.78M -8.35% | |
| Operating Margin | -220.90% | -190,006.15% | -361,104.92% | -2,527,171.76% | N/A | -757,890.98% | |
| EPS YoY % growth | -15.00 45.67% | -15.60 -4.00% | -15.80 -1.28% | -15.77 0.19% | -14.85 5.82% | -6.77 54.40% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -3.65 -1.53% | -3.71 -9.00% | -4.02 -0.39% | -3.80 -5.54% |
| Revenue Q2Q % growth | -100.00% | -100.00% | -100.00% | -100.00% |
| EBITDA Q2Q % growth | -53.326M -28.18% | -61.455M -71.18% | -63.903M -48.49% | N/A |
| EBIT Q2Q % growth | -59.053M -14.60% | -60.282M -19.36% | -61.787M 1.40% | -60.18M -4.90% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -3.60 25.00% | -3.67 | 0.07 | 1.96% |
| Q4 2024 Q2Q % growth | -4.00 | -3.47 | -0.53 | -15.34% |
| Q3 2024 Q2Q % growth | -3.40 | -4.08 | 0.68 | 16.67% |
| Q2 2024 Q2Q % growth | -3.60 | -4.18 | 0.58 | 13.92% |
| Q1 2024 Q2Q % growth | -4.80 -4.35% | -4.28 | -0.52 | -12.04% |
| Q4 2023 Q2Q % growth | -4.00 -400.00% | -4.65 | 0.65 | 14.00% |
| Q3 2023 Q2Q % growth | -3.40 39.29% | -5.10 | 1.70 | 33.33% |
| Q2 2023 Q2Q % growth | -3.60 -20.00% | -5.58 | 1.98 | 35.44% |
| Q1 2023 Q2Q % growth | -4.60 17.86% | -5.78 | 1.18 | 20.41% |
| Q4 2022 Q2Q % growth | -0.80 88.57% | -6.19 | 5.39 | 87.07% |
| Q3 2022 Q2Q % growth | -5.60 -40.00% | -6.32 | 0.72 | 11.45% |
| Q2 2022 Q2Q % growth | -3.00 83.15% | -6.32 | 3.32 | 52.56% |
| Q1 2022 Q2Q % growth | -5.60 | -5.85 | 0.25 | 4.24% |
| Q4 2021 Q2Q % growth | -7.00 | -5.61 | -1.39 | -24.78% |
| Q3 2021 Q2Q % growth | -4.00 | -5.51 | 1.51 | 27.38% |
| Q2 2021 Q2Q % growth | -17.80 | -7.45 | -10.35 | -139.05% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | 7K 133.33% | 7K | % | |
| Q4 2024 Q2Q % growth | 11K -15.38% | 11K | % | |
| Q3 2024 Q2Q % growth | 34K 36.00% | 34K | % | |
| Q2 2024 Q2Q % growth | 13K -51.85% | 13K | % | |
| Q1 2024 Q2Q % growth | 3K -95.38% | 3K | % | |
| Q4 2023 Q2Q % growth | 13K -99.97% | 13K | % | |
| Q2 2023 Q2Q % growth | 27K -99.92% | 27K | % | |
| Q1 2023 Q2Q % growth | 65K -88.18% | 65K | % | |
| Q4 2022 Q2Q % growth | 48.39M 1,615.96% | 1.904M | 46.486M | 2,441.49% |
| Q3 2022 Q2Q % growth | -100.00% | 1.836M | -1.836M | -100.00% |
| Q2 2022 Q2Q % growth | 35.74M 1,258.94% | 1.088M | 34.652M | 3,184.93% |
| Q1 2022 Q2Q % growth | 550K -77.55% | 1.02M | -470K | -46.08% |
| Q4 2021 Q2Q % growth | 2.82M 22.08% | 2.907M | -87K | -2.99% |
| Q3 2021 Q2Q % growth | 2.76M 157.94% | 2.346M | 414K | 17.65% |
| Q2 2021 Q2Q % growth | 2.63M -15.71% | 2.295M | 335K | 14.60% |
| Q1 2021 Q2Q % growth | 2.45M 94.44% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -3.86% | -1967.35% | -10.04% | -1996.27% |
| Revenue | N/A | N/A | -64.09% | N/A |